{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T17:01:49Z","timestamp":1789837309306,"version":"4.0.1"},"reference-count":12,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Acute Myeloid Leukemia (AML) has a peak incidence in elderly patients with the median age of onset being 68 years. Owing to the advanced age and multiple comorbidities, such patients are not candidates for the standard chemotherapeutic protocols. Here we discuss the treatment strategies employed for newly diagnosed elderly patients with AML at our institution and their associated outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>We conducted a single institutional retrospective review of cases which included elderly patients aged \u2265 50 years diagnosed with AML and treated with venetolcax in combination with azacitidine. Data relating to patients\u2019 characteristics, cytogenetics, molecular aberrations and vital status were extracted. We evaluated the overall survival (OS) as our primary outcome of interest.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>This study involved 58 patients with confirmed AML, with a median age of 61.5 years. The majority of patients were male (77.6%). Most patients (75.9%) died, while 15.5% were still under treatment at the end of the study period. The median OS was 7.0 months. There was no significant difference in survival based on comorbid conditions (p = 0.586). However, survival differed by gender, with a median OS of 6 months for males and 16 months for females (p = 0.021). The number of chemotherapy cycles significantly impacted survival, with increased cycles associated with a reduced hazard of death (HR = 0.74, p &lt; 0.01).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our findings contribute to the growing evidence that venetoclax combined with azacitidine is an effective treatment option for elderly patients with AML who are not eligible for intensive treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2478\/jcas-2025-0001","type":"journal-article","created":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T16:07:37Z","timestamp":1789834057000},"page":"1-7","source":"Crossref","is-referenced-by-count":0,"title":["Outcomes of patients with Acute Myeloid Leukemia receiving venetoclax in combination with azacitidine: A single center retrospective study from Pakistan"],"prefix":"10.2478","volume":"11","author":[{"given":"Junaid","family":"Alam","sequence":"first","affiliation":[{"name":"Aga Khan University Hospital Karachi , Sindh PAKISTAN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lavita","family":"Kumari","sequence":"additional","affiliation":[{"name":"Aga Khan University Hospital Karachi , Sindh PAKISTAN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usman","family":"Shaikh","sequence":"additional","affiliation":[{"name":"Aga Khan University Hospital Karachi , Sindh PAKISTAN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akbar Khan","family":"Muhammad Ali","sequence":"additional","affiliation":[{"name":"Aga Khan University Hospital Karachi , Sindh PAKISTAN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2025,5,29]]},"reference":[{"key":"2026091916073308263_j_jcas-2025-0001_ref_001","doi-asserted-by":"crossref","unstructured":"Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937\u201351.","DOI":"10.1182\/blood-2009-03-209262"},{"key":"2026091916073308263_j_jcas-2025-0001_ref_002","doi-asserted-by":"crossref","unstructured":"Skopek R, Palusi\u0144ska M, Kaczor-Keller K, Pingwara R, Papierniak-Wygl\u0105da\u0142a A, Schenk T, et al. Choosing the Right Cell Line for Acute Myeloid Leukemia (AML) Research. Int J Mol Sci. 2023;24(6).","DOI":"10.3390\/ijms24065377"},{"key":"2026091916073308263_j_jcas-2025-0001_ref_003","doi-asserted-by":"crossref","unstructured":"Sajid R, Moiz B, Ali N, Kamran N, Adil AN, Shaikh U, et al. Therapeutic outcomes of older patients with acute myeloid leukemia. Saudi Med J. 2010;31(5):533\u20138.","DOI":"10.15537\/1658-3175.5028"},{"key":"2026091916073308263_j_jcas-2025-0001_ref_004","doi-asserted-by":"crossref","unstructured":"DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133(1):7\u201317.","DOI":"10.1182\/blood-2018-08-868752"},{"key":"2026091916073308263_j_jcas-2025-0001_ref_005","doi-asserted-by":"crossref","unstructured":"Vachhani P, Flahavan EM, Xu T, Ma E, Montez M, Gershon A, et al. Venetoclax and Hypomethylating Agents as First-line Treatment in Newly Diagnosed Patients with AML in a Predominately Community Setting in the US. Oncologist. 2022;27(11):907\u201318.","DOI":"10.1093\/oncolo\/oyac135"},{"key":"2026091916073308263_j_jcas-2025-0001_ref_006","doi-asserted-by":"crossref","unstructured":"Cheng EH, Wei MC, Weiler S, Flavell RA, Mak TW, Lindsten T, et al. BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. Mol Cell. 2001;8(3):705\u201311.","DOI":"10.1016\/S1097-2765(01)00320-3"},{"key":"2026091916073308263_j_jcas-2025-0001_ref_007","unstructured":"Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: International Agency for Research on Cancer; 2017 2017\/\/."},{"key":"2026091916073308263_j_jcas-2025-0001_ref_008","doi-asserted-by":"crossref","unstructured":"D\u00f6hner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, B\u00fcchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424\u201347.","DOI":"10.1182\/blood-2016-08-733196"},{"key":"2026091916073308263_j_jcas-2025-0001_ref_009","doi-asserted-by":"crossref","unstructured":"Garciaz S, Hospital MA, Alary AS, Saillard C, Hicheri Y, Mohty B, et al. Azacitidine Plus Venetoclax for the Treatment of Relapsed and Newly Diagnosed Acute Myeloid Leukemia Patients. Cancers (Basel). 2022;14(8).","DOI":"10.3390\/cancers14082025"},{"key":"2026091916073308263_j_jcas-2025-0001_ref_010","unstructured":"Mirgh S, Sharma A, Shaikh M, Kadian K, Agrawal N, Khushoo V, et al. Hypomethylating agents+venetoclax induction therapy in acute myeloid leukemia unfit for intensive chemotherapy - novel avenues for lesser venetoclax duration and patients with baseline infections from a developing country. Am J Blood Res. 2021;11(3):290\u2013302."},{"key":"2026091916073308263_j_jcas-2025-0001_ref_011","doi-asserted-by":"crossref","unstructured":"Pollyea DA, Pratz K, Letai A, Jonas BA, Wei AH, Pullarkat V, et al. Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow-up from a phase 1b study. American Journal of Hematology. 2021;96(2):208\u201317.","DOI":"10.1002\/ajh.26039"},{"key":"2026091916073308263_j_jcas-2025-0001_ref_012","doi-asserted-by":"crossref","unstructured":"Todisco E, Papayannidis C, Fracchiolla N, Petracci E, Zingaretti C, Vetro C, et al. AVALON: The Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed\/refractory patients with acute myeloid leukemia. Cancer. 2023;129(7):992\u20131004.","DOI":"10.1002\/cncr.34608"}],"container-title":["Journal of Cancer and Allied Specialties"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/reference-global.com\/pdf\/10.2478\/jcas-2025-0001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T16:07:45Z","timestamp":1789834065000},"score":1,"resource":{"primary":{"URL":"https:\/\/reference-global.com\/article\/10.2478\/jcas-2025-0001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,1]]},"references-count":12,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,5,29]]},"published-print":{"date-parts":[[2025,1,1]]}},"alternative-id":["10.2478\/jcas-2025-0001"],"URL":"https:\/\/doi.org\/10.2478\/jcas-2025-0001","relation":{},"ISSN":["2411-989X"],"issn-type":[{"value":"2411-989X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,1]]}}}